A Screening Models of (In Vivo And In Vitro) Used for the Study of Hepatoprotective Agents

Abstract

In order to evaluate hepatoprotective function, both in vitro and in vivo liver or hepatoprotective models have been constructed in the past. These methods examine a drug's potential to prevent or minimize liver damage in test animals. To express their effectiveness and safety in humans, new drugs must first travel through a number of developmental phases, beginning with the identification of their pharmacological characteristics in cellular and animal models. In the medical literature, there are many methods for measuring hepatoprotective efficacy in vivo and in vitro. Fresh hepatocytes are exposed to hepatotoxin treatment in in vitro models, and the effects of the test chemical on those cells are examined. To elicit liver damage in test animals, dangerous dosages of an identified hepatotoxin are administered in in vivo models. The test material is provided before, after, and simultaneously with the toxin treatment. Hepatitis in Long Evans and other chemical agents are commonly exploited to generate hepatotoxicity in experimental animals for the evaluation of hepatoprotective medications. Cinnamon rats, liver cirrhosis and necrosis, hepatic fibrosis brought on by carbon tetrachloride in rats, liver cirrhosis brought on by galactosamine, inhibition of proline hydroxylation, trans-heptic investigations model in dogs, etc. The many forms of in vivo and in vitro hepatoprotective screening models are explained in this article.